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To the Editor,
Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was seen first in Wuhan, China and
spread very quickly all over the world despite very
strict precautions taken worldwide1. The World Health
Organisation (WHO) declared the disease a pandemic
on March 11, 2020. Turkey reported its first case of the
coronavirus on the same day and had started taking
precautions both in the country and along the borders
months earlier. Over time, many case reports and
remarkable articles relating to the disease progression,
virus genomics, and treatment options were published in
high-quality journals. Simultaneously, country-wide data
registries and research activities began in Turkey. Recently,
a correspondence sent from Turkey offering a critique of
some important points concerning the disease, including
transmission routes to Turkey (mainly Iran and Saudi
Arabia), lack of transparency at the Turkish Ministry
of Health (MoH), and, in particular, scientific research
restrictions on COVID-19 was published in Lancet, one
of the most prestigious medical journals [1]. We read the
correspondence of Hasan Bayram et al. with great interest.
It reported important information concerning COVID-19
transmission routes to Turkey, a lack of transparency by
the Turkish MoH, and purported restrictions on scientific
research on COVID-19.
We would like to address some concerns mentioned
by Bayram et al. For instance, the authors claim that
COVID-19 reached Turkey mainly through Iran and Saudi
Arabia; however, research indicates many different origins
for the disease in Turkey. The SARS-CoV-2 genome was
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phylogenetically analyzed in Turkish laboratories and
in laboratories around the world, and the results were
documented in the global initiative on sharing all influenza
data (GISAID) platform2 . Karacan et al. analyzed the
viral isolates of three COVID-19–positive patients and
found that all three isolates carried the D614G variant
in the S gene, indicating that they are all in the G clade,
which was mostly detected in European countries [2]. In
addition, Adebali et al. performed a phylogenetic analysis
of the first thirty SARS-CoV-2 genomes isolated and
sequenced in Turkey [3]. Their analysis suggested multiple
independent international introductions of the virus to
the country. They clustered the genomes based on their
clade distribution in the phylogenetic tree and found that
most samples from Turkey belong to cluster four, which is
also prevalent in Iran, Denmark, and France. They found
a connection to Saudi Arabia in only two cities in Turkey,
while the Europe-based introductions were identified
in the genomes isolated from İstanbul, the epicenter of
Turkey’s COVID-19 outbreak. In addition, according to
Turkish Ministry of Culture and Tourism data on border
introduction counts between January and March, Iran
and Saudi Arabia accounted for only 6.72% of all visitors
(5.19% from Iran and 1.53% from Saudi Arabia). During
the same interval, entry from Europe constituted 38.52%
of all visitors (24.88% from OECD countries and 13.79%
from non-OECD countries)3. The first COVID-19–
positive cases were seen within the same day in Iran and
Europe, nearly 20 days before Turkey’s first documented
case. Furthermore, Turkey closed its border with Iran
on February 23 after Iran’s first cases of COVID-19
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were confirmed on February 19; however, flights to and
from Italy, one of the European countries most affected
by COVID-19, were not cancelled until February 29.
Additionally, Turkish visitors returning from pilgrimages
in Saudi Arabia were checked with thermal cameras
before boarding and were quarantined in select isolated
hostels for 14 days. Considering all this well-documented
information, attributing virus introduction to only one or
two sources seems illogical.
The authors’ next point, that there is a lack of
transparency at the Turkish MoH, has already been
addressed by the organization in its daily briefings on
the MoH website and on social media4. The authors’
most controversial subject is the alleged restrictions
on COVID-19 research. The rumours about research
restrictions are simply not true. In fact, the timely responses
of the Turkish MoH to research applications encouraged
researchers to work faster and more efficiently. According
to data from the official MoH website, nearly 5000 research
applications regarding COVID-19 were submitted online,
and the MoH approved more than 96% of them within five
days, allowing researchers to proceed with their proposed
studies5. Local institutes and councils also supported many
trials concerning COVID-19 [2,3].
Finally, in addition to this objective data, Turkey’s
official agencies, healthcare workers, and community
have come together to quell the COVID-19 outbreak as
successfully as any other country. Personal protective
equipment (PPE) was produced in collaboration with
formal and private agencies and distributed all around the
country. Moreover, Turkey has supported many countries,
including the United States and the United Kingdom, with

Table. Fatality and mortality rates calculated according to current
population of countries1,2.
Countries

Fatality rate

Mortality rate

Turkey

0.024

0.07

United States of America

0.031

0.50

United Kingdom

0.131

0.60

Belgium

0.129

0.86

France

0.152

0.47

Spain

0.083

0.61

Italy

0.139

0.59

1
Worlddometer (2020). Countries in the World by population [online].
Website https://www.worldometers.info/world-population/populationby-country [accessed 16 August 2020].
2
WHO (2020). COVID-19 Dashboard (death counts) [online]. Website
https://covid19.who.int/ [accessed 16 August 2020].

PPE. Two large emergency hospitals were built in İstanbul
and began providing services in only 45 days. In addition,
mechanical ventilators were produced with 100% local
resources for the first time and delivered to local hospitals.
With mass production, Turkey was able to manufacture
enough ventilators to export to other countries. As a result
of these proactive and effective steps, Turkey has had lower
mortality rates than many developed countries (Table).
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